The complex and dynamic landscape of multimodal cancer care is boosting demand for oncology-specific technological innovations. The need for elevated cancer care is steadily climbing, compelling software developers to create increasingly integrated and sophisticated solutions. Oncology has always been at the forefront of digitization due to the substantial amount of data needed and generated for each patient during the treatment process. Today, advanced oncology software offers clinicians a
Read More
Precision Oncology
Quest Diagnostics Acquires Haystack Oncology for $300M in Cash
What You Should Know: Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
Accelerating Clinical Trials Through AI-Enabled Precision Oncology
The American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mortality rates and increased trial diversity. However, there is still much work to be done. Especially with the multiple types of new and ongoing challenges clinicians and staff members are facing - such as high turnover rates, decreased budgets and increased feelings of burnout - taking the necessary steps to enhance clinical trial procedures is crucial
Read More
COTA and GTC Partner to Improve Precision Oncology
What You Should Know: - COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. - GTC has a very innovative approach to genetic testing, providing molecular information which is critical to determining accurate diagnoses and determining the most appropriate treatment. GTC's tissue and liquid-biopsy testing leverages DNA and RNA sequencing, which is very rare in the
Read More
Pangea Biomed Adds $5M for its Multi-Cancer Response Predictor
What You Should Know: - Pangea Biomed, the biotech company behind ENLIGHT, the multi-cancer response predictor improving the effectiveness of precision oncology, announced $5M in additional funding reaching a total seed round of $12M. - The latest fundraising is led by angel investor Danny Tocatly and existing investor NFX, and will be used to expand US operations, drive commercial partnerships, and scale product offerings. Expanding US Operations and Fostering Commercial
Read More
Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech
What You Should Know: - Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know: - Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records. - Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
Tavros Therapeutics Raises $7.5M to Develop Targeted Cancer Therapies
What You Should Know: - Tavros Therapeutics, a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities raises $7.5 million in Seed II financing co-led by existing investor Piedmont Capital Investments and new investor KdT Ventures, with participation from Alexandria Venture Investments. - Tavros launched in 2020 with a $3 million seed financing by Piedmont Capital Investments and a strategic collaboration with Zentalis
Read More
Elevation Oncology Secures $50M Loan Facility with K2 HealthVentures
What You Should Know: Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior secured loan facility from funds managed by K2 HealthVentures. Elevation plans to use the funding from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the
Read More
Syapse and Pierian Partner to Power Precision Oncology
What You Should Know: - Syapse, a real-world evidence company is teaming up with Pierian®, a provider of advanced clinical genomics technology on a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida. - The collaboration combines Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer, Pierian’s leading-edge clinical genomics workflow, and precision medicine services that provide the most relevant
Read More
